Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?
Standard
Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens? / Bokemeyer, Carsten.
In: J CLIN ONCOL, Vol. 26, No. 11, 11, 2008, p. 1783-1785.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Bokemeyer, C 2008, 'Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?', J CLIN ONCOL, vol. 26, no. 11, 11, pp. 1783-1785. <http://www.ncbi.nlm.nih.gov/pubmed/18398143?dopt=Citation>
APA
Bokemeyer, C. (2008). Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens? J CLIN ONCOL, 26(11), 1783-1785. [11]. http://www.ncbi.nlm.nih.gov/pubmed/18398143?dopt=Citation
Vancouver
Bokemeyer C. Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens? J CLIN ONCOL. 2008;26(11):1783-1785. 11.
Bibtex
@article{d48c2c38f249444ba276f7a1b079ad2c,
title = "Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?",
author = "Carsten Bokemeyer",
year = "2008",
language = "Deutsch",
volume = "26",
pages = "1783--1785",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",
}
RIS
TY - JOUR
T1 - Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?
AU - Bokemeyer, Carsten
PY - 2008
Y1 - 2008
M3 - SCORING: Zeitschriftenaufsatz
VL - 26
SP - 1783
EP - 1785
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 11
M1 - 11
ER -
